Fresenius Majority-Owned Group Mabxience Has Licensing Agreement With Intas Pharmaceuticals for Autoimmune Disease Drug Etanercept

Author: Charles Gross | December 20, 2023 06:02am

 Intas Pharmaceuticals Ltd., a leading multinational pharmaceutical company, has announced today a strategic exclusive licensing agreement with mAbxience (a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma) for a biosimilar for Etanercept. Etanercept is a dimeric fusion protein with tumor necrosis factor (TNF) blocking action that was approved for use over 20 years ago, offering patients a valuable therapeutic option for treating various autoimmune diseases. According to IQVIA, global sales of Etanercept for 12 months, ending June 2023, were $ 11B.

• Intas gains exclusive commercialization rights for the Etanercept biosimilar, for more than 150 countries worldwide.
• This collaboration with mAbxience strengthens the Intas global biosimilar portfolio, underscoring its commitment to further grow the pipeline through collaborations and increasing access to high-quality medicines globally.
• mAbxience will be responsible for the development, manufacturing, and supply of the Etanercept biosimilar.
• This collaboration marks a significant step forward in providing enhanced global access to advanced treatments for autoimmune diseases.

Posted In: FMS